NP 011
Alternative Names: NP-011Latest Information Update: 17 Aug 2023
Price :
$50 *
At a glance
- Originator NEXEL
- Class Anti-inflammatories; Antifibrotics; Heart failure therapies; Hepatoprotectants; Recombinant proteins
- Mechanism of Action MFGE8 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Myocardial infarction
- Preclinical Alcoholic hepatitis; Non-alcoholic steatohepatitis; Ulcerative colitis
Most Recent Events
- 26 May 2023 Nexel and Novotech completes a phase I trial in Myocardial infarction (In volunteers) in Australia (IV) (NCT05387499)
- 28 May 2022 Nexel plans a phase I trial in Non-alcoholic steatohepatitis in South Korea in mid 2022
- 28 May 2022 Nexel plans a phase II trial in Myocardial infarction, Non-alcoholic steatohepatitis and Ulcerative colitis in 2023